Hub : Traits :

Birth weight of first child

177 significantly associated models · 58 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	752566	1916587	1	1	1.3e-07	3.3e-06	5.6e-01	98	SCNN1D
2	1	11181327	12600396	1	2	3.9e-10	2.4e-11	8.8e-02	94	CLCN6
3	2	8934921	10394558	1	1	1.7e-08	1.5e-07	3.7e-01	97	ADAM17
4	2	10886098	12295638	1	1	4.8e-08	7.0e-08	1.0e+00	100	E2F6
5	3	122306920	123860565	2	1	1.4e-12	1.8e-11	2.7e-01	97	ADCY5
6	3	140350567	141867638	1	1	6.0e-08	1.1e-07	1.0e+00	100	ZBTB38
7	3	155070465	156966235	3	1	1.3e-21	3.5e-22	3.9e-02	95	KCNAB1
8	4	17104059	18507692	1	1	3.9e-08	4.2e-08	2.9e-02	84	DCAF16
9	4	105598022	107092169	1	1	1.6e-12	2.8e-16	4.1e-08	55	PPA2
10	4	145203531	146706624	1	1	1.1e-09	2.5e-10	1.4e-02	85	ANAPC10
11	6	34528785	36158878	5	3	4.3e-13	1.1e-12	5.5e-02	93	C6orf126 TEAD3 ZNF76
12	8	22687572	24125172	1	1	1.0e-07	4.5e-07	6.7e-02	87	SLC25A37
13	8	140969818	142706843	1	1	3.8e-09	8.9e-06	5.5e-01	98	PTK2
14	10	70696908	71273696	2	1	2.2e-08	1.3e-10	7.4e-04	72	SUPV3L1
15	10	95379543	96818402	1	3	2.2e-15	3.9e-14	1.0e+00	100	NOC3L
16	10	103905779	105647095	4	1	5.7e-08	9.1e-08	1.0e+00	100	NT5C2
17	11	101228512	102802722	3	1	3.0e-11	8.7e-12	1.0e+00	100	RP11-864G5.3
18	12	30084002	31526510	1	1	4.2e-10	2.4e-08	7.3e-01	100	IPO8
19	15	74488424	76108550	2	1	8.0e-08	8.7e-07	6.7e-01	99	MPI
20	15	85227407	86990983	2	1	3.3e-09	1.3e-12	7.8e-05	69	RP11-158M2.3
21	15	90718541	92135418	2	2	2.3e-15	7.7e-13	9.6e-02	95	FES
22	17	16718225	18194248	1	1	8.7e-08	2.6e-11	1.0e-06	46	PEMT
23	17	79298590	80694826	1	1	1.1e-08	6.9e-08	2.5e-01	95	DCXR
24	20	30984239	31508152	1	1	2.3e-07	1.1e-05	1.7e-04	27	C20orf203

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	2.84	2	2	4.4	0.00	1.0e+00	FES NT5C2
Depressed Affect (Nagel 2018)	1.29	1	0	0.0	0.00	1.0e+00	PTK2
Intelligence (Savage-Jansen 2018)	1.92	3	2	4.4	0.00	1.0e+00	DCAF16 PPA2 PTK2
Neuroticism (Nagel 2018)	1.10	1	0	0.0	0.00	1.0e+00	NT5C2
Schizophrenia (2018)	2.80	2	2	4.4	0.00	1.0e+00	FES NT5C2
Schizophrenia vs Biploar Disorder	1.29	1	0	0.0	0.00	1.0e+00	PTK2
Worry (Nagel 2018)	0.94	1	1	2.2	0.00	1.0e+00	NT5C2
Crohns Disease (2017)	1.59	1	1	2.2	0.00	1.0e+00	ZBTB38
Irritable Bowel Disease (IBD)	1.92	2	0	0.0	0.00	1.0e+00	IPO8 TEAD3
Ulcerative Colitis (UC)	2.10	3	0	0.0	0.00	1.0e+00	IPO8 PPA2 TEAD3
Major Depression (MDD)	2.19	1	0	0.0	0.00	1.0e+00	FES
Verbal and Numeric Reasoning (VNR)	2.07	2	2	4.4	0.00	1.0e+00	DCAF16 PPA2
Breast Cancer	1.95	3	1	2.2	0.21	7.9e-01	FES MPI ZBTB38
Prostate Cancer	2.18	1	0	0.0	0.00	1.0e+00	ZBTB38
Coronary Artery Disease (CAD)	3.01	2	0	0.0	0.00	1.0e+00	NT5C2 PEMT
Crohns Disease (2012)	1.41	1	0	0.0	0.00	1.0e+00	ZBTB38
LDL Cholesterol	1.31	1	0	0.0	0.00	1.0e+00	MPI
Lupus	1.94	2	0	0.0	0.00	1.0e+00	MPI ZNF76
Schizophrenia (2014)	2.66	2	2	4.4	0.00	1.0e+00	FES NT5C2
Blood Eosinophil Count	1.38	6	2	4.4	-0.55	2.6e-01	ADCY5 C20orf203 C6orf126 RP11-158M2.3 TEAD3 ZNF76
Blood Platelet Count	1.04	9	3	6.7	-0.08	8.2e-01	ADCY5 CLCN6 DCAF16 MPI NT5C2 RP11-158M2.3 RP11-864G5.3 SLC25A37 SUPV3L1
Blood Red Count	2.23	8	4	8.9	0.28	4.3e-01	C20orf203 CLCN6 DCXR FES MPI RP11-158M2.3 TEAD3 ZBTB38
Blood White Count	1.54	8	4	8.9	-0.50	1.7e-01	DCAF16 FES NT5C2 PPA2 PTK2 RP11-864G5.3 SUPV3L1 ZNF76
Heel T-Score	1.54	5	5	11.1	-0.45	4.5e-01	ANAPC10 DCAF16 DCXR ZBTB38 ZNF76
BMI	1.35	5	3	6.7	0.66	2.2e-01	CLCN6 DCAF16 MPI NT5C2 SLC25A37
Height	9.55	15	13	28.9	0.59	9.8e-03	ADAM17 ADCY5 ANAPC10 C6orf126 DCAF16 DCXR FES IPO8 NOC3L NT5C2 PPA2 RP11-864G5.3 TEAD3 ZBTB38 ZNF76
Waist Hip Ratio (WHR)	2.85	10	3	6.7	-0.60	6.9e-02	ADAM17 ANAPC10 C6orf126 DCXR IPO8 MPI NOC3L PEMT PTK2 ZBTB38
Systolic Blood Pressure	10.13	9	6	13.3	-0.73	1.1e-02	CLCN6 DCAF16 FES MPI NOC3L NT5C2 RP11-158M2.3 SCNN1D SLC25A37
Smoking Status	2.48	3	1	2.2	0.99	1.3e-02	FES NT5C2 PTK2
Allergy or Eczema	2.52	4	1	2.2	-0.23	7.1e-01	CLCN6 FES MPI ZBTB38
Cardiovascular Disease	6.74	6	4	8.9	-0.65	7.8e-02	CLCN6 DCAF16 FES MPI NOC3L ZNF76
Hypothyroidism (self reported)	1.53	3	1	2.2	0.00	1.0e+00	PTK2 SCNN1D SLC25A37
Respiratory disease	1.85	2	1	2.2	0.00	1.0e+00	FES ZNF76
Lung FEV1/FVC ratio	2.41	6	2	4.4	0.53	2.2e-01	ADAM17 C20orf203 NOC3L PPA2 ZBTB38 ZNF76
Lung FVC	2.98	10	8	17.8	0.61	6.2e-02	ANAPC10 C6orf126 DCAF16 DCXR IPO8 PPA2 SUPV3L1 TEAD3 ZBTB38 ZNF76
Neuroticism	1.06	1	0	0.0	0.00	1.0e+00	NT5C2
Hair Pigment	1.04	6	4	8.9	0.75	5.5e-02	C20orf203 DCXR FES PEMT ZBTB38 ZNF76
Tanning	0.40	4	1	2.2	0.51	4.9e-01	C20orf203 MPI NT5C2 TEAD3
Hand grip strength (left)	2.79	5	2	4.4	0.92	2.6e-02	DCAF16 FES NT5C2 ZBTB38 ZNF76
Number of treatments/medications taken	1.92	2	0	0.0	0.00	1.0e+00	DCAF16 FES
Sensitivity / hurt feelings	1.97	1	1	2.2	0.00	1.0e+00	FES
Hearing difficulty/problems: Yes	1.60	1	1	2.2	0.00	1.0e+00	PTK2
Relative age of first facial hair	0.96	1	0	0.0	0.00	1.0e+00	ZBTB38
Other serious medical condition/disability diagnosed by doctor	1.38	1	0	0.0	0.00	1.0e+00	PPA2
Systolic blood pressure, automated reading	8.29	7	6	13.3	-0.93	2.5e-04	CLCN6 DCAF16 FES MPI NT5C2 PPA2 SCNN1D
Angina	2.76	1	1	2.2	0.00	1.0e+00	FES
Impedance of leg (right)	1.54	5	2	4.4	-0.64	1.7e-01	FES IPO8 NT5C2 PPA2 PTK2
Leg fat-free mass (left)	5.44	11	5	11.1	0.75	8.1e-03	ANAPC10 DCAF16 FES IPO8 NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Trunk fat percentage	2.11	8	2	4.4	-0.35	3.9e-01	ADCY5 C6orf126 CLCN6 DCXR MPI SLC25A37 TEAD3 ZBTB38
Hand grip strength (right)	2.31	4	2	4.4	0.97	3.0e-02	DCAF16 NT5C2 ZBTB38 ZNF76
Current tobacco smoking	1.89	1	0	0.0	0.00	1.0e+00	NT5C2
Average weekly fortified wine intake	1.28	1	0	0.0	0.00	1.0e+00	C20orf203
Maternal smoking around birth	1.33	1	0	0.0	0.00	1.0e+00	NT5C2
Age when periods started (menarche)	1.30	1	0	0.0	0.00	1.0e+00	PEMT
High blood pressure	7.43	6	3	6.7	-0.88	4.2e-03	CLCN6 DCAF16 FES MPI PTK2 TEAD3
Hayfever, allergic rhinitis or eczema	2.19	2	1	2.2	0.00	1.0e+00	MPI ZBTB38
Stomach or abdominal pain in last month	0.95	1	0	0.0	0.00	1.0e+00	PPA2
Medication: Atenolol	3.93	1	1	2.2	0.00	1.0e+00	FES
Medication: Levothyroxine sodium	1.29	1	0	0.0	0.00	1.0e+00	SCNN1D
Sitting height	8.58	11	7	15.6	0.66	1.4e-02	ADCY5 ANAPC10 DCAF16 DCXR FES NOC3L NT5C2 PPA2 TEAD3 ZBTB38 ZNF76
Chronic bronchitis/emphysema (father)	1.58	1	0	0.0	0.00	1.0e+00	PTK2
High blood pressure (mother)	6.17	3	1	2.2	-0.60	2.9e-01	CLCN6 FES MPI
Body mass index (BMI)	1.31	5	0	0.0	0.58	3.0e-01	CLCN6 DCAF16 MPI NT5C2 SLC25A37
Impedance of leg (left)	1.56	4	2	4.4	-0.58	3.1e-01	FES NT5C2 PPA2 PTK2
Leg predicted mass (left)	5.45	11	5	11.1	0.75	8.0e-03	ANAPC10 DCAF16 FES IPO8 NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Trunk fat mass	2.66	8	3	6.7	0.50	2.1e-01	ADCY5 ANAPC10 CLCN6 DCXR MPI NT5C2 SLC25A37 ZBTB38
Waist circumference	1.85	6	2	4.4	0.55	2.6e-01	ADCY5 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Number of incorrect matches in round	1.50	2	0	0.0	0.00	1.0e+00	FES NT5C2
Past tobacco smoking	2.04	1	1	2.2	0.00	1.0e+00	NT5C2
Alcohol usually taken with meals	1.93	1	0	0.0	0.00	1.0e+00	FES
Nervous feelings	1.24	1	1	2.2	0.00	1.0e+00	NT5C2
Hearing difficulty/problems with background noise	1.53	1	0	0.0	0.00	1.0e+00	MPI
Had other major operations	1.87	1	0	0.0	0.00	1.0e+00	PPA2
Forced vital capacity (FVC)	7.07	9	8	17.8	0.97	1.6e-05	ANAPC10 C6orf126 DCAF16 DCXR IPO8 PPA2 TEAD3 ZBTB38 ZNF76
Heel bone mineral density (BMD) T-score, automated (right)	1.07	2	0	0.0	0.00	1.0e+00	DCAF16 ZBTB38
Qualifications: None of the above	1.85	2	0	0.0	0.00	1.0e+00	PPA2 PTK2
Financial difficulties in last 2 years	1.26	1	0	0.0	0.00	1.0e+00	MPI
Mouth/teeth dental problems	1.45	1	0	0.0	0.00	1.0e+00	PTK2
Heart attack	2.60	1	1	2.2	0.00	1.0e+00	FES
Allergy	2.09	4	1	2.2	-0.29	6.4e-01	CLCN6 FES ZBTB38 ZNF76
Medication: Ramipril	2.41	2	0	0.0	0.00	1.0e+00	FES MPI
Medication: Simvastatin	2.64	1	1	2.2	0.00	1.0e+00	FES
Fluid intelligence score	2.47	2	2	4.4	0.00	1.0e+00	DCAF16 PPA2
Illnesses of siblings	3.02	2	1	2.2	0.00	1.0e+00	CLCN6 FES
Weight	4.09	9	6	13.3	0.66	5.2e-02	ADCY5 ANAPC10 CLCN6 DCAF16 MPI NT5C2 PPA2 SLC25A37 ZBTB38
Impedance of arm (right)	0.95	1	0	0.0	0.00	1.0e+00	RP11-864G5.3
Arm fat percentage (right)	1.82	6	2	4.4	-0.35	5.0e-01	CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Trunk fat-free mass	7.15	11	7	15.6	0.78	4.8e-03	ADAM17 ANAPC10 C6orf126 DCAF16 NOC3L NT5C2 PPA2 PTK2 TEAD3 ZBTB38 ZNF76
Hip circumference	3.47	8	5	11.1	0.67	4.7e-02	ADCY5 ANAPC10 CLCN6 DCXR NT5C2 PEMT SLC25A37 ZBTB38
Father's age at death	3.34	2	1	2.2	0.00	1.0e+00	FES NOC3L
Worrier / anxious feelings	1.17	1	1	2.2	0.00	1.0e+00	NT5C2
Frequency of tiredness / lethargy in last 2 weeks	1.23	1	0	0.0	0.00	1.0e+00	MPI
Forced expiratory volume in 1-second (FEV1)	7.24	10	8	17.8	0.96	1.1e-06	ANAPC10 C6orf126 DCAF16 DCXR IPO8 NOC3L PPA2 TEAD3 ZBTB38 ZNF76
Pulse rate	1.94	2	1	2.2	0.00	1.0e+00	RP11-864G5.3 ZBTB38
Qualifications: A levels/AS levels or equivalent	1.40	1	0	0.0	0.00	1.0e+00	PPA2
Mouth/teeth dental problems: Dentures	1.67	1	0	0.0	0.00	1.0e+00	KCNAB1
Asthma	2.28	2	1	2.2	0.00	1.0e+00	ZBTB38 ZNF76
Medication: Cholesterol lowering	3.37	2	1	2.2	0.00	1.0e+00	CLCN6 FES
Illnesses of mother	3.71	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), Best measure	7.61	10	9	20.0	0.96	9.8e-07	ANAPC10 C6orf126 DCAF16 DCXR IPO8 NOC3L PPA2 TEAD3 ZBTB38 ZNF76
Pulse wave Arterial Stiffness index	2.71	2	0	0.0	0.00	1.0e+00	FES NT5C2
Impedance of arm (left)	0.91	2	0	0.0	0.00	1.0e+00	RP11-864G5.3 TEAD3
Arm fat mass (right)	1.91	6	1	2.2	0.92	1.0e-02	ANAPC10 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Trunk predicted mass	7.15	11	7	15.6	0.78	4.9e-03	ADAM17 ANAPC10 C6orf126 DCAF16 NOC3L NT5C2 PPA2 PTK2 TEAD3 ZBTB38 ZNF76
Standing height	9.33	12	11	24.4	0.72	3.8e-03	ADAM17 ADCY5 ANAPC10 C6orf126 DCAF16 IPO8 NOC3L NT5C2 PPA2 TEAD3 ZBTB38 ZNF76
Breastfed as a baby	2.20	2	0	0.0	0.00	1.0e+00	FES SCNN1D
Hair/balding pattern: Pattern 4	1.81	2	1	2.2	0.00	1.0e+00	FES ZBTB38
Peak expiratory flow (PEF)	3.82	7	3	6.7	0.76	4.9e-02	ANAPC10 DCAF16 MPI NT5C2 PPA2 SCNN1D ZNF76
Mouth/teeth dental problems: Bleeding gums	1.91	1	0	0.0	0.00	1.0e+00	PPA2
Medication: Paracetamol	2.12	1	1	2.2	0.00	1.0e+00	PTK2
Headache pain in last month	1.59	2	0	0.0	0.00	1.0e+00	FES IPO8
Medication for cholesterol, blood pressure or diabetes	5.56	3	2	4.4	0.72	1.7e-01	CLCN6 FES MPI
Hypothyroidism/myxoedema (self-reported)	1.35	2	0	0.0	0.00	1.0e+00	PTK2 SCNN1D
Medication: Amlodipine	3.45	2	1	2.2	-1.00	2.6e-03	CLCN6 FES
Birth weight	9.70	15	9	20.0	0.98	1.5e-10	ADAM17 ADCY5 ANAPC10 C6orf126 DCAF16 FES NT5C2 PPA2 PTK2 RP11-158M2.3 RP11-864G5.3 SLC25A37 SUPV3L1 TEAD3 ZNF76
High blood pressure (siblings)	4.15	2	2	4.4	-0.29	7.1e-01	CLCN6 FES
Forced vital capacity (FVC), Best measure	7.13	10	8	17.8	0.97	1.3e-06	ANAPC10 C6orf126 DCAF16 DCXR IPO8 NOC3L PPA2 TEAD3 ZBTB38 ZNF76
Body fat percentage	1.98	8	1	2.2	-0.35	3.9e-01	C6orf126 CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZBTB38 ZNF76
Leg fat percentage (right)	1.99	6	1	2.2	-0.31	5.5e-01	CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Arm fat-free mass (right)	5.96	11	7	15.6	0.63	3.9e-02	ADAM17 ADCY5 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Exposure to tobacco smoke outside home	1.06	1	0	0.0	0.00	1.0e+00	NT5C2
Comparative body size at age 10	1.09	1	1	2.2	0.00	1.0e+00	SUPV3L1
Worry too long after embarrassment	1.23	1	0	0.0	0.00	1.0e+00	PPA2
Age at first live birth	1.34	2	0	0.0	0.00	1.0e+00	DCAF16 PTK2
Pulse wave peak to peak time	2.41	2	0	0.0	0.00	1.0e+00	FES NT5C2
Qualifications: College or University degree	2.11	5	3	6.7	0.65	2.3e-01	DCAF16 PPA2 PTK2 RP11-864G5.3 ZBTB38
Medication for pain relief, constipation, heartburn	1.84	1	0	0.0	0.00	1.0e+00	PTK2
Neck or shoulder pain in last month	1.38	1	0	0.0	0.00	1.0e+00	PTK2
Medication: Blood pressure	6.39	3	2	4.4	-0.73	1.6e-01	CLCN6 FES MPI
Angina (self-reported)	2.81	1	1	2.2	0.00	1.0e+00	FES
Mean time to correctly identify matches	1.19	1	0	0.0	0.00	1.0e+00	FES
Whole body fat mass	2.25	7	1	2.2	0.53	2.2e-01	ADCY5 ANAPC10 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Leg fat mass (right)	1.98	6	1	2.2	0.57	2.4e-01	ADCY5 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Arm predicted mass (right)	5.96	11	7	15.6	0.63	3.9e-02	ADAM17 ADCY5 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Pulse rate, automated reading	2.18	4	2	4.4	0.94	6.5e-02	DCXR E2F6 RP11-864G5.3 ZBTB38
Alcohol intake frequency.	1.32	1	0	0.0	0.00	1.0e+00	PPA2
Comparative height size at age 10	6.88	11	6	13.3	0.79	3.7e-03	ADAM17 ANAPC10 C6orf126 DCAF16 FES NT5C2 PPA2 SUPV3L1 TEAD3 ZBTB38 ZNF76
Suffer from 'nerves'	1.33	1	0	0.0	0.00	1.0e+00	NT5C2
Medication: Aspirin	2.53	1	1	2.2	0.00	1.0e+00	FES
Knee pain experienced in last month	2.30	1	0	0.0	0.00	1.0e+00	PTK2
Hypertension (Self-reported)	7.49	6	3	6.7	-0.68	6.6e-02	CLCN6 DCAF16 FES MPI PTK2 SLC25A37
Illnesses of father: Heart disease	4.36	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), predicted	7.05	7	4	8.9	0.97	2.2e-04	ANAPC10 DCAF16 NT5C2 PPA2 TEAD3 ZBTB38 ZNF76
Whole body fat-free mass	6.54	11	7	15.6	0.87	4.4e-04	ADAM17 ANAPC10 DCAF16 IPO8 NOC3L NT5C2 PPA2 SLC25A37 TEAD3 ZBTB38 ZNF76
Leg fat-free mass (right)	5.51	11	5	11.1	0.75	8.1e-03	ANAPC10 DCAF16 FES IPO8 NOC3L NT5C2 PPA2 PTK2 SLC25A37 ZBTB38 ZNF76
Arm fat percentage (left)	1.77	6	2	4.4	-0.37	4.8e-01	CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Average weekly red wine intake	1.21	1	0	0.0	0.00	1.0e+00	MPI
Handedness (chirality/laterality): Left-handed	1.55	1	0	0.0	0.00	1.0e+00	FES
Mood swings	1.55	1	1	2.2	0.00	1.0e+00	PTK2
Qualifications: nursing, teaching	1.23	1	0	0.0	0.00	1.0e+00	PPA2
Medication for cholesterol	2.19	2	0	0.0	0.00	1.0e+00	CLCN6 FES
Back pain experienced in last month	2.34	1	0	0.0	0.00	1.0e+00	PTK2
Asthma (self-reported)	2.34	2	1	2.2	0.00	1.0e+00	ZBTB38 ZNF76
Osteoarthritis (self-reported)	1.78	2	0	0.0	0.00	1.0e+00	MPI PTK2
Medication: Aspirin	2.68	1	1	2.2	0.00	1.0e+00	FES
Illnesses of father: None of the above (group 1)	3.65	1	1	2.2	0.00	1.0e+00	FES
Smoking status: Current	1.95	1	1	2.2	0.00	1.0e+00	NT5C2
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.81	4	2	4.4	0.97	2.6e-02	ANAPC10 PPA2 TEAD3 ZNF76
Whole body water mass	6.48	12	7	15.6	0.77	3.2e-03	ADAM17 ANAPC10 DCAF16 IPO8 NOC3L NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Leg predicted mass (right)	5.53	12	5	11.1	0.75	4.6e-03	ANAPC10 DCAF16 FES IPO8 NOC3L NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Arm fat mass (left)	1.86	5	1	2.2	0.93	2.2e-02	CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Number of self-reported non-cancer illnesses	2.22	2	0	0.0	0.00	1.0e+00	CLCN6 ZNF76
Average weekly champagne plus white wine intake	1.98	2	0	0.0	0.00	1.0e+00	DCXR RP11-864G5.3
Medication: Blood pressure	4.86	3	3	6.7	-0.80	1.0e-01	CLCN6 FES MPI
High cholesterol (Self-reported)	2.17	2	0	0.0	0.00	1.0e+00	CLCN6 DCAF16
Medication: Bendroflumethiazide	3.16	3	1	2.2	-0.95	5.1e-02	CLCN6 FES MPI
Medication: Paracetamol	1.99	1	0	0.0	0.00	1.0e+00	PTK2
Illnesses of father: High blood pressure	4.86	1	1	2.2	0.00	1.0e+00	FES
Ever smoked	2.16	3	1	2.2	0.00	1.0e+00	FES NT5C2 PPA2
Basal metabolic rate	5.99	12	6	13.3	0.65	2.2e-02	ADAM17 ADCY5 ANAPC10 DCAF16 IPO8 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Leg fat percentage (left)	2.11	6	1	2.2	-0.32	5.4e-01	CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Arm fat-free mass (left)	5.87	10	6	13.3	0.73	1.6e-02	ADAM17 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Number of operations (self-reported)	2.68	2	1	2.2	0.00	1.0e+00	PPA2 SCNN1D
Risk taking	2.04	1	0	0.0	0.00	1.0e+00	FES
Ever had prostate specific antigen (PSA) test	1.44	1	0	0.0	0.00	1.0e+00	ZBTB38
Diastolic blood pressure, automated reading	6.89	7	4	8.9	-0.53	1.4e-01	CLCN6 DCAF16 FES MPI NOC3L SLC25A37 ZNF76
Vascular/heart problems diagnosed by doctor	7.58	6	3	6.7	0.87	5.4e-03	CLCN6 DCAF16 FES MPI PTK2 TEAD3
Cholesterol lowering medication	1.48	1	0	0.0	0.00	1.0e+00	DCAF16
Pain experienced in last month	1.62	1	0	0.0	0.00	1.0e+00	PTK2
Heart attack/myocardial infarction (self-reported)	2.62	2	1	2.2	0.00	1.0e+00	FES TEAD3
Heart disease (siblings)	1.98	1	0	0.0	0.00	1.0e+00	FES
Impedance of whole body	1.17	3	1	2.2	0.00	1.0e+00	NT5C2 PPA2 PTK2
Leg fat mass (left)	2.01	6	2	4.4	0.57	2.4e-01	ADCY5 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Arm predicted mass (left)	5.86	10	6	13.3	0.73	1.6e-02	ADAM17 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	6	0.172	1.9
GTEx	Adipose Visceral Omentum	3	0.147	1.9
GTEx	Adrenal Gland	2	0.137	1.8
GTEx	Artery Aorta	4	0.134	1.9
GTEx	Artery Coronary	1	0.085	1.9
GTEx	Artery Tibial	10	0.266	2.0
GTEx	Brain Caudate basal ganglia	1	0.109	1.8
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.9
GTEx	Brain Cerebellum	3	0.151	1.9
GTEx	Brain Cortex	1	0.097	1.8
GTEx	Brain Frontal Cortex BA9	0	0.000	1.8
GTEx	Brain Hippocampus	0	0.000	1.8
GTEx	Brain Hypothalamus	1	0.169	1.8
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.8
GTEx	Brain Putamen basal ganglia	0	0.000	1.6
GTEx	Breast Mammary Tissue	2	0.101	1.8
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.8
GTEx	Breast Mammary Tissue (Female)	3	0.182	1.8
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.9
GTEx	Cells Transformed fibroblasts	5	0.119	1.9
GTEx	Colon Sigmoid	1	0.068	1.9
GTEx	Colon Transverse	2	0.097	1.8
GTEx	Esophagus Gastroesophageal Junction	1	0.069	1.9
GTEx	Esophagus Mucosa	5	0.151	1.9
GTEx	Esophagus Muscularis	4	0.124	1.9
GTEx	Heart Atrial Appendage	3	0.190	1.8
GTEx	Heart Left Ventricle	2	0.131	1.8
GTEx	Liver	0	0.000	1.8
GTEx	Lung	6	0.209	1.9
GTEx	Muscle Skeletal	0	0.000	1.8
GTEx	Nerve Tibial	9	0.208	1.8
GTEx	Ovary	1	0.110	1.9
GTEx	Pancreas	1	0.061	1.8
GTEx	Pituitary	0	0.000	2.0
GTEx	Prostate	1	0.120	1.8
GTEx	Skin Not Sun Exposed Suprapubic	4	0.163	1.9
GTEx	Skin Sun Exposed Lower leg	6	0.165	1.9
GTEx	Small Intestine Terminal Ileum	0	0.000	1.8
GTEx	Spleen	3	0.213	1.8
GTEx	Stomach	2	0.138	2.0
GTEx	Testis	2	0.063	1.8
GTEx	Thyroid	3	0.075	1.8
GTEx	Uterus	1	0.176	2.0
GTEx	Vagina	0	0.000	2.0
GTEx	Whole Blood	1	0.050	1.8
METSIM	Adipose	6	0.130	1.8
NTR	Blood	3	0.125	1.9
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.8
YFS	Blood	4	0.087	1.8
CommonMind	Brain Pre-frontal Cortex	9	0.167	1.8
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	6	0.136	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.9
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.7
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	4	0.147	1.9
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	1	0.024	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	1	0.049	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	1	0.023	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	0	0.000	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	5	0.170	1.8
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	3	0.065	1.8
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.9
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.7
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.178	1.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.9